{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70","upperLimit":"85","value":"78"},{"groupId":"OG001","lowerLimit":"33","upperLimit":"71","value":"52"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"21","value":"14"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"36","value":"17"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"9","value":"4"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"12","value":"0"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"3","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"18","value":"3"}]}],"title":"PD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"3","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"12","value":"0"}]}],"title":"Non-evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"4","value":"1"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"27","value":"10"}]}],"title":"Undefined/ No Disease"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"8","value":"3"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"36","value":"17"}]}],"title":"Not Done"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"BOR was defined as percentage of participants with CR, PR, stable disease(SD), disease progression(PD), non-evaluable(NE), undefined/no disease or not done as best response to treatment by the Lugano Classification. CR and PR defined in OM#1. SD/no metabolic response(NMR):score 4(uptake moderately greater than (\\>) liver) or 5(uptake markedly\\>liver and/ or new lesions) with no significant change in fluorodeoxyglucose(FDG) uptake compared to baseline(screening), at interim time point or end of treatment; no new sites of disease should be observed. PD:score 4(uptake moderately\\>liver) or 5(uptake markedly\\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. Not done:no assessment at time of analysis. Percentages were rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"NUMBER","populationDescription":"Participants in the Full Analysis Set with available data were analyzed","reportingStatus":"POSTED","timeFrame":"Up to 85.6 months","title":"Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}